BRINGING IMPACT IN THREE THERAPEUTIC AREAS
We are laser-focused on developing innovative treatments within our three therapeutic areas: oncology, neuroscience and rare disease. We believe that concentrating on diseases and disorders within these areas, we can make a positive impact on the lives of patients and their families.
Our products are the result of decades of experience and years of research and development. We are proud of the portfolio of medicines we have brought to market, and we are determined in our efforts to find the next wave of treatments for patients.
Product names, availability, and indicated uses may vary by country. Not all products are available in all countries. Please consult your local Ipsen website for more information on the products available in your region. Patients should always ask a healthcare professional for advice.
Our products
Filter
Disease Areas
Showing: 1 – 05 of 10 Product
Iqirvo® (elafibranor)
Iqirvo is an oral, once-daily, peroxisome proliferator-activated receptor alpha/delta (PPAR α/δ) agonist approved for primary biliary cholangitis (PBC). Activation of PPARα inhibits molecules that promote inflammation, it decreases bile toxicity and mitigates oxidative stress. PPARδ enhances bile flow, energy metabolism and anti-fibrotic pathways. The dual activation of PPAR-α and PPAR-δ works synergistically to address cholestasis, inflammation, and fibrosis in PBC. Iqirvo has been granted accelerated approval in the US and conditional approval in EU for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Onivyde® (irinotecan liposome injection)
This consists of a lipid bilayer vesicle, or liposome, that encapsulates irinotecan in an aqueous space and is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Sohonos® (palovarotene)
Palovarotene is an orally bioavailable retinoic acid receptor gamma (RARγ) to treat patient with fibrodysplasia ossificans progressiva (FOP). Sohonos® is proposed for the prevention of Heterotopic Ossification (HO) in adults and children (girls over eight, boys over 10) with FOP.
Somatuline® (lanreotide acetate)
A synthetic (analog) version of the natural hormone somatostatin, which is found naturally in the human body. Used for the treatment of neuroendocrine tumors (NETs) and acromegaly, as well as the symptoms associated with neuroendocrine, (particularly carcinoid) tumors.
Tazverik® (tazemetostat)
This oral methyltransferase inhibitor selectively inhibits mutant (MT) and wild-type (WT) Enhancer of Zeste Homolog 2 (EZH2). It is approved in the US for the treatment of patients over 16 with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. It can also be used for adults with relapsed or refractory follicular lymphoma with EZH2 mutation-positive tumors who have received at least two prior systemic therapies, or for adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Request medical information / report adverse event or product complaint
To request medical information on Ipsen’s products, report an adverse event or report a complaint, please visit: Ipsen Medical Information or email us at globalmedinfo@ipsen.com
Adverse event reactions can also be reported directly to Ipsen’s local safety team using the contact details provided in the contact us pages
Related contact
-
Product & Medical Information
-
